Pharma industry stakeholders are generally quick to suggest that the Czech Republic is one of the most over-regulated markets in Europe, with new or…

Patrik Zachar, Vice President Central Europe of Ipsen, shares how the company has built a strong presence in oncology and neuroscience in the CE…

These are worrying times for iconic French mid-cap Ipsen. Trials for palovarotene, a treatment for rare bone disorders, have been plagued by setbacks,…

Khaled Elrefae, Middle East and Africa Specialty Care Operations Head (GM) for Ipsen, highlights Ipsen’s impressive internationalization strategy…

With a feel-good factor sweeping French innovative pharma, the country’s iconic mid-cap biopharma standard-bearers are once more on the rise. These…

Nick Lee, general manager of Ipsen Taiwan, Hong Kong, and Macau, shares his journey of building up the affiliate after having separated from their…

The latest issue of Healthcare & Life Sciences Review France follows on from our March 2019 report and takes a closer look at the wider French…

Bringing together insights from the heads of some of Europe's most prominent mid-cap pharma firms. The leaders of Ipsen, Genmab, Pierre Fabre, Esteve…

France is rediscovering its mojo. After a period of relative stagnation, the country’s highly strategic USD 65 billion healthcare and life sciences…

Min-Young Kim, general manager at Ipsen Korea discusses her strategy to refocus the Korean affiliate away from the toxin market and towards oncology…

Following on from Johnson & Johnson’s acquisition of Actelion in January 2017 and Takeda’s takeover of Shire two years later, pharma…

This is the first in a series of articles examining what it takes to be a country manager of a multinational pharma company in some of the world’s…